MIMS Group, an Asia-Pacific provider of medicines information and clinical decision support, is accelerating product innovation and international growth under the leadership of Group CEO Sohil Goswami, who was appointed in January 2026. The company is reshaping its businesses and leadership structure to harness its data, technology, and healthcare relationships to create scalable products and new business models across markets. This move signals a significant shift from traditional information services to technology-enabled platforms, positioning MIMS to compete globally in the digital health landscape.
The company recently launched MIMS Pulse, a next-generation Clinical Decision Support platform that combines MIMS' medicines data and clinical knowledge with modern technology, flexible deployment, and integration capabilities to support safer and more efficient clinical workflows. Alongside MIMS Pulse, MIMS is scaling eMIMS Plus, a platform that brings trusted medicines information into a modern digital experience designed to achieve quality use of medicine. First launched in Australia under Goswami's guidance, eMIMS Plus is now available in India and Malaysia, with plans to expand across Southeast Asia, introduce new clinical modules, and extend into new healthcare categories through Drugs4Dent. MIMS is developing its global CDS offering, building on these platforms to take its clinical data and technology capabilities into new markets and customer environments.
MIMS' Medical Communications business is also expanding internationally, with commercial capabilities in the US and UK creating opportunities with new client segments and global life sciences organizations. The business continues to develop digital events, AI-enabled content capabilities, and new customer engagement models. MIMS is exploring more connected, intelligence-led services to help healthcare and life sciences organizations better understand their markets, engage healthcare professionals, and make more informed decisions. This represents a step beyond traditional information and communications models, applying content data and market reach to new technology-enabled services.
Goswami said: "For decades, healthcare professionals have trusted MIMS' medicines information and expertise. Today, we are transforming that foundation into the next generation of digital products, platforms and services. We have been reshaping the business – bringing our capabilities together, strengthening our technology and building new ways to serve customers across markets. Our opportunity is to turn trusted medical data, deep healthcare relationships and market knowledge into the next generation of products, platforms and services to build a MIMS that can compete and grow globally while staying relevant to the markets we serve."
The developments form part of a broader evolution across MIMS as the company builds on its established strengths while extending its products, capabilities, and reach into new areas of healthcare. With a presence in 17 markets and over two million healthcare professional subscribers, MIMS is leveraging its six decades of trusted medical data and expertise to drive innovation. The company's transformation is poised to impact how healthcare professionals access and use medical information, ultimately improving patient outcomes. This news matters because it underscores the growing role of AI and digital platforms in healthcare, and MIMS' strategic shift could set a precedent for other traditional medical information providers seeking to remain relevant in a rapidly evolving digital landscape. For more information, visit https://corporate.mims.com/. The announcement was distributed via Media OutReach Newswire.
